%0 Journal Article %J Eur.J.Clin.Microbiol.Infect.Dis. %D 1988 %T Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in Belgium36631 %A R. Vanhoof %A Hubrechts,J.M. %A Nyssen,H.J. %A Roebben,E. %K 0 %K a %K Agent %K Agents %K Amikacin %K Anti-Bacterial Agents %K article %K bacteria %K Belgium %K Brussels %K Change %K Dibekacin %K drug effects %K Drug Resistance,Microbial %K Drug Utilization %K effect %K general %K Gentamicins %K hospital %K Hospitals,General %K Humans %K im %K Institute %K IS %K journal %K Laboratories %K Less %K LEVEL %K levels %K medical %K Netilmicin %K observed %K ON %K p %K pharmacology %K Print %K resistance %K SB - IM %K study %K survey %K therapeutic use %K Tobramycin %K use %X The aim of the study was to evaluate the effect of intensive use of amikacin on the resistance levels to amikacin, gentamicin, tobramycin, netilmicin and dibekacin. The base-line resistance in the preamikacin phase (three months of amikacin use less than 1%; 676 isolates) was 1.0% for amikacin, 11.4% for gentamicin, 8.0% tobramycin, 6.2% for netilmicin and 8.3% for dibekacin. During the amikacin phase (36 months of average amikacin use of 89%; 6048 isolates) there was no significant change in aminoglycoside resistance except for dibekacin (from 8.3% to 10.9%, 0.05 greater than p greater than 0.02). Isolated amikacin resistance was not observed %B Eur.J.Clin.Microbiol.Infect.Dis. %V 7 %P 183 - 185 %8 0/4/1988 %G eng %N 2 %1 36631 %& 183